JPS6365945A - Preparation of microcapsule - Google Patents
Preparation of microcapsuleInfo
- Publication number
- JPS6365945A JPS6365945A JP20798886A JP20798886A JPS6365945A JP S6365945 A JPS6365945 A JP S6365945A JP 20798886 A JP20798886 A JP 20798886A JP 20798886 A JP20798886 A JP 20798886A JP S6365945 A JPS6365945 A JP S6365945A
- Authority
- JP
- Japan
- Prior art keywords
- water
- phase separation
- microcapsules
- producing microcapsules
- soluble
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003094 microcapsule Substances 0.000 title claims abstract description 53
- 239000000126 substance Substances 0.000 claims abstract description 30
- 238000005191 phase separation Methods 0.000 claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 20
- 229920000642 polymer Polymers 0.000 claims abstract description 13
- -1 fatty acid ester Chemical class 0.000 claims abstract description 12
- 235000010445 lecithin Nutrition 0.000 claims abstract description 11
- 239000000787 lecithin Substances 0.000 claims abstract description 11
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 10
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 10
- 239000000194 fatty acid Substances 0.000 claims abstract description 10
- 229930195729 fatty acid Natural products 0.000 claims abstract description 10
- 229940067606 lecithin Drugs 0.000 claims abstract description 10
- 108010010803 Gelatin Proteins 0.000 claims abstract description 8
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 8
- 229920000159 gelatin Polymers 0.000 claims abstract description 8
- 239000008273 gelatin Substances 0.000 claims abstract description 8
- 235000019322 gelatine Nutrition 0.000 claims abstract description 8
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 8
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims abstract description 7
- 230000001939 inductive effect Effects 0.000 claims abstract description 7
- 229960003194 meglumine Drugs 0.000 claims abstract description 7
- 229920002678 cellulose Polymers 0.000 claims abstract description 4
- 239000001913 cellulose Substances 0.000 claims abstract description 4
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 claims abstract description 4
- UJMBCXLDXJUMFB-GLCFPVLVSA-K tartrazine Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-GLCFPVLVSA-K 0.000 claims abstract description 4
- 235000012756 tartrazine Nutrition 0.000 claims abstract description 4
- 229960000943 tartrazine Drugs 0.000 claims abstract description 4
- 239000004149 tartrazine Substances 0.000 claims abstract description 4
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 claims abstract description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000004472 Lysine Substances 0.000 claims abstract description 3
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 claims abstract description 3
- 235000012732 erythrosine Nutrition 0.000 claims abstract description 3
- 229940011411 erythrosine Drugs 0.000 claims abstract description 3
- 239000004174 erythrosine Substances 0.000 claims abstract description 3
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 229930006000 Sucrose Natural products 0.000 claims description 8
- 239000000411 inducer Substances 0.000 claims description 8
- 239000005720 sucrose Substances 0.000 claims description 8
- 229920002307 Dextran Polymers 0.000 claims description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 5
- 239000004475 Arginine Substances 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 239000000975 dye Substances 0.000 abstract description 8
- 239000011248 coating agent Substances 0.000 abstract description 4
- 238000000576 coating method Methods 0.000 abstract description 4
- 238000000034 method Methods 0.000 description 25
- 239000000243 solution Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 150000002148 esters Chemical class 0.000 description 8
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 6
- 239000007791 liquid phase Substances 0.000 description 6
- 229940042585 tocopherol acetate Drugs 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 239000011162 core material Substances 0.000 description 5
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000084 colloidal system Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 3
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 235000019645 odor Nutrition 0.000 description 2
- 229940083466 soybean lecithin Drugs 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000008291 lyophilic colloid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/06—Making microcapsules or microballoons by phase separation
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Abstract
Description
【発明の詳細な説明】
(1)産業上の利用分野
本発明は水難溶性物質を芯物質とするマイクロカプセル
の製造方法に関する。従って本発明は医薬品9食品、製
紙、写真用フィルムの各分野において利用することがで
きるが、とりわけ油状物質の粉末化、不安定物質の経時
的安定化、物質の味。DETAILED DESCRIPTION OF THE INVENTION (1) Field of Industrial Application The present invention relates to a method for producing microcapsules whose core material is a poorly water-soluble substance. Therefore, the present invention can be used in the fields of pharmaceuticals, foods, paper manufacturing, and photographic films, but is particularly applicable to the pulverization of oily substances, the stabilization of unstable substances over time, and the taste of substances.
臭の隠蔽化に有効であり、かつ生体に対し安全性の高い
物質のみを使用するので、医薬品の分野において特に利
用される。It is particularly useful in the pharmaceutical field because it is effective in masking odors and uses only substances that are highly safe for living organisms.
(2)従来技術と問題点
マイクロカプセルの製造については、従来から多数の方
法が提供されてきた。最も多用されてきた方法はいわゆ
る相分離法であり1例えばマイクロカプセルの皮膜とな
る物質を無機塩類やエタノールの添加あるいはpH調整
により芯物質のまわりに相分離させる方法がしばしば採
用されてきた。(2) Prior Art and Problems Many methods have been proposed for the production of microcapsules. The most commonly used method is the so-called phase separation method.1 For example, a method in which a material that forms the film of a microcapsule is phase-separated around a core material by adding inorganic salts or ethanol or by adjusting the pH has often been adopted.
また低沸点溶媒に水不溶性高分子を溶解しておき加熱蒸
発によって芯物質表面に強制的に析出させるとか、ある
いは温度を変化調節して溶解度を減少させ、芯物質表面
に析出させ、それぞれ皮膜化させる方法もあり2時には
採用されてきた。しかしこれらの従来方法にはそれぞれ
に困雑な問題点が知られている。最も大きな問題点は操
作が複雑で熟練を要することである。例えば、従来の相
分離法では相分離を長時間をかけて徐々に完成させる必
要があり、その成否は操作者の熟練に負う所が大きく1
条件設定の不備によりカプセル同志が粘着凝集する失敗
に至る。また皮膜を硬化させるためにホルムアルデヒド
等を添加しなければならないが、完成品から余剰のホル
ムアルデヒドを完全に除去することが困難であり、特に
相分離マイクロカプセルを医薬品や食品の分野で利用す
る場合に問題点となる。これはジクロロエタンやシクロ
ヘキサン等の低沸点溶媒を使用する方法の場合にも同様
の問題点として起る。すなわち加熱による溶媒除去や冷
却による溶解度低下の操作自体が複雑で時間のかかる操
作であり、操作者の高度の熟練を必要とするが、同時に
残留溶媒を完全に除去することは困難であり、医薬品や
食品の分野では大きな問題点となる。Alternatively, a water-insoluble polymer can be dissolved in a low-boiling point solvent and forced to precipitate on the surface of the core material by heating and evaporating, or the solubility can be decreased by adjusting the temperature and precipitated on the surface of the core material, forming a film. There is also a method of setting the clock to 2:00, which has been used. However, each of these conventional methods is known to have its own troublesome problems. The biggest problem is that the operation is complicated and requires skill. For example, in conventional phase separation methods, it is necessary to gradually complete phase separation over a long period of time, and its success or failure largely depends on the skill of the operator.
Inadequate setting of conditions led to a failure in which the capsules adhered to each other and agglomerated together. In addition, formaldehyde must be added to harden the film, but it is difficult to completely remove excess formaldehyde from the finished product, especially when phase-separated microcapsules are used in the pharmaceutical and food fields. This becomes a problem. This problem also occurs in methods using low boiling point solvents such as dichloroethane and cyclohexane. In other words, the operations of removing solvent by heating and reducing solubility by cooling are complex and time-consuming operations that require a high level of skill on the part of the operator. This is a major problem in the food and food industries.
(3)問題点を解決するための手段
上記した問題点にかんがみ9本発明者は特別な熟練も必
要とせずに単純簡便な操作によって相分離マイクロカプ
セルを瞬時に調製することのできる技術の開発を目的と
して種々の検討を行った。(3) Means for Solving the Problems In view of the above-mentioned problems9, the present inventors have developed a technique that allows phase-separated microcapsules to be instantly prepared by simple and convenient operations without requiring any special skill. Various studies were conducted with this aim.
その結果、意外にも芯物質である水難溶性物質をあらか
じめショ糖脂肪酸エステルあるいはレシチンによって被
覆しておくだけで所期の目的が達成されることを見出し
2本発明を完成するに至っ總以下に本発明の詳細な説明
する。As a result, they unexpectedly discovered that the intended purpose could be achieved simply by coating the core substance, which is a poorly water-soluble substance, with sucrose fatty acid ester or lecithin in advance.2 This led to the completion of the present invention. The present invention will be described in detail.
本発明が解決しようとする対象は水難溶性物質の相分離
マイクロカプセルである。水1溶性物質とは水に任意の
割合で混和しない、あるいは溶解しない物質を言い、固
体状、半固体状、液体状のいづれであってもよく1例え
ばビタミンA、 D、 E。The object to be solved by the present invention is phase-separated microcapsules for poorly water-soluble substances. A water-soluble substance refers to a substance that does not mix or dissolve in water in any proportion, and may be in solid, semi-solid, or liquid form, such as vitamins A, D, and E.
K等の脂溶性ビタミン類、水難溶性ビタミン類。Fat-soluble vitamins such as K, poorly water-soluble vitamins.
動物油、植物油、鉱物油2合成油などをあげることがで
きる。Examples include animal oil, vegetable oil, mineral oil, 2 synthetic oils, etc.
相分離とは高分子溶液やコロイド電解質溶液のごとき親
液コロイド溶液が条件の変化によりコロイドに富む液相
とコロイドに乏しい液相との二つの液相に分離する現象
を言い、いわゆるコアセルベーションとも言われ、マイ
クロカプセルを製造するための一つの手段として利用さ
れる。本発明における相分離は本発明に係る皮膜形成性
高分子組成物のコロイド溶液が誘起剤の添加によりコロ
イドに富む液相とコロイドに乏しい液相とに分離する現
象を言い、相分離後コロイドに富む液相(コアセルベー
ト)は水難溶性物質の周囲に堆漬し2次第に水分を失っ
て皮膜となり、マイクロカプセルを形成するに至る。本
発明においてマイクロカプセルは平均直径が50〜10
0ミクロンの球形または紡錐形の粒子として得られるが
、平均直径は任意に調節することができる。Phase separation is a phenomenon in which a lyophilic colloid solution such as a polymer solution or a colloidal electrolyte solution separates into two liquid phases, a colloid-rich liquid phase and a colloid-poor liquid phase, due to changes in conditions, and is called coacervation. Also called microcapsules, it is used as a means for manufacturing microcapsules. Phase separation in the present invention refers to a phenomenon in which a colloidal solution of the film-forming polymer composition according to the present invention separates into a colloid-rich liquid phase and a colloid-poor liquid phase by the addition of an inducing agent. The rich liquid phase (coacervate) is deposited around the poorly water-soluble substance and gradually loses water to form a film, leading to the formation of microcapsules. In the present invention, the microcapsules have an average diameter of 50 to 10
It is obtained as spherical or cone-shaped particles of 0 micron, but the average diameter can be adjusted arbitrarily.
皮膜形成性高分子組成物とは相分離により皮膜を形成す
るに至る一以上の高分子からなる組成物を8い、該高分
子としては例えば、ゼラチン、カゼイン、フィブリノー
ゲンのごときポリペブタイド、デキストラン、アラビヤ
ゴム、キト酸のごとキ多糖類1 ヒドロキシプロピル
メチルセルロース。A film-forming polymer composition refers to a composition consisting of one or more polymers that form a film through phase separation, and examples of such polymers include gelatin, casein, polypeptides such as fibrinogen, dextran, and gum arabic. , chitic acid, chipolysaccharide 1, hydroxypropyl methylcellulose.
ヒドロキシプロピルセルロース、メチルセルロースのご
とき非イオン性セルロース誘導体を挙げることができる
。例えばゼラチン、デキストラン。Nonionic cellulose derivatives such as hydroxypropylcellulose and methylcellulose can be mentioned. For example, gelatin, dextran.
ヒドロキシプロピルメチルセルロースの組合わせは好ま
しい組成物の一つであり、この場合に組成比はゼラチン
1重量部に対しデキストランおよびヒドロキシメチルセ
ルロースはそれぞれ1〜4重量部が適当であり、また相
分離をさせるにあたっての組成物の水溶液中の濃度は2
〜20%W/Vが適当であり、特に4〜1α’N/Vが
好ましい。The combination of hydroxypropyl methylcellulose is one of the preferred compositions, and in this case, the appropriate composition ratio is 1 to 4 parts by weight each of dextran and hydroxymethylcellulose to 1 part by weight of gelatin. The concentration of the composition in an aqueous solution is 2
~20% W/V is appropriate, and 4-1α'N/V is particularly preferred.
しかし本発明はこれらの組成比および濃度に限定される
ことはな(2選択した高分子の種類によって適宜に決定
すればよい。However, the present invention is not limited to these composition ratios and concentrations (2) They may be appropriately determined depending on the type of selected polymer.
組成物水溶液の調製は組成物を構成する各高分子を個別
に水に溶解してから混合すればよいが。The composition aqueous solution may be prepared by individually dissolving each polymer constituting the composition in water and then mixing them.
これに限定されない。It is not limited to this.
本発明の特徴は水難溶性物質をショ糖脂肪酸エステルま
たはレシチンによって被覆してから、相分離のための誘
起剤を添加することにある。ここでショ糖脂肪酸エステ
ルは一般にシュガーエステルの名称で市販されているも
のを入手して使用すればよい。シュガーエステルの種類
については特に限定はないが2例えばシュガーエステル
S−970(リョウトウ産業)が好ましい。レシチンに
ついても特に限定はな(、大豆レシチン、卵黄レシチン
およびそれらの水添レシチンを適宜に選択して使用すれ
ばよい。ショ糖脂肪酸エステルおよびレシチンを組合せ
て使用してもよい。使用量は水難溶性物質1重量部に対
して0.1〜1重量部が適当であるが、目的とするマイ
クロカプセルの粒径あるいは水難溶性物質が固体、半固
体、液体のいづれの状態であるかに応じて、要は水難溶
性物質が(まなく被覆されるのに必要な量を決定すれば
よく9本発明はこの使用量によって限定されない。A feature of the present invention is that a poorly water-soluble substance is coated with sucrose fatty acid ester or lecithin, and then an inducer for phase separation is added. Here, as the sucrose fatty acid ester, those commercially available under the name of sugar ester may be obtained and used. The type of sugar ester is not particularly limited, but for example, Sugar Ester S-970 (Ryoto Sangyo) is preferred. There are no particular limitations on lecithin (soybean lecithin, egg yolk lecithin, and their hydrogenated lecithins may be selected and used as appropriate. Sucrose fatty acid esters and lecithin may be used in combination. The amount used is determined by water standards. The appropriate amount is 0.1 to 1 part by weight per 1 part by weight of the soluble substance, but it depends on the particle size of the target microcapsules or whether the poorly water-soluble substance is in a solid, semi-solid, or liquid state. In short, it is only necessary to determine the amount necessary to completely coat the poorly water-soluble substance (9) The present invention is not limited by this amount.
被覆には例えば次のような方法が推奨される。まず少量
の水またはエタノールにショ糖脂肪酸エステルまたはレ
シチンを加温溶解し、この中に水難溶性物質を分散また
は溶解してお(。次に水を激しく撹拌しながら、この水
中に上記によってあらかじめ調製しておいた液を徐々に
投入する。これにより水難溶性物質の分散粒の周囲にシ
ョ糖脂肪酸エステルまたはレシチンの被覆が完成する。For example, the following methods are recommended for coating. First, warm and dissolve sucrose fatty acid ester or lecithin in a small amount of water or ethanol, and disperse or dissolve the poorly water-soluble substance therein.Next, while vigorously stirring the water, add the previously prepared Gradually pour in the solution that has been prepared.This completes the coating of the sucrose fatty acid ester or lecithin around the dispersed particles of the poorly water-soluble substance.
従って例えば皮膜形成性高分子組成物の水溶液を激しく
撹拌しながら、この中にあらかじめ調製しておいた液を
徐々に投入すればよい。しかしこれは本発明の好ましい
態様例を示したにすぎない。次に相分離のための誘起剤
はコロイドの凝結剤、沈澱剤として一般に公知の物質を
入手して使用すればよいが2本発明においては例えばメ
グルミン。Therefore, for example, while vigorously stirring an aqueous solution of a film-forming polymer composition, a previously prepared solution may be gradually poured into the solution. However, this is merely an example of a preferred embodiment of the invention. Next, as an inducer for phase separation, any substance generally known as a coagulant or precipitant for colloids may be obtained and used. In the present invention, for example, meglumine is used.
アルギニン、リジン、ヒスチジン、ロイシン、イソロイ
シン、バリンを挙げることができる。また意外にもエリ
スロシン、タートラジン、サンセットイエロー、ブリリ
アントブルーのごとき水溶性色素も本発明の誘起剤とし
て機能することが判った。さらにこの場合にはこれら色
素による遮光性着色マイクロカプセルが得られる。誘起
剤の添加量は少量でよく、具体的には誘起剤の水溶液を
あらかじめ用意しておき、すでにショ糖脂肪酸エステル
またはレシチンの被覆が完成している液をゆる(撹拌し
ながら、この中に徐々に滴下し、顕微鏡で相分離の進行
を観察しながら、所定の相分離が完成するのに必要な量
を加えればよい。従って誘起剤の添加量および添加方法
は状況に応じて適宜に定めて行なえばよい。多(の場合
に相分離は5〜15分程度の短時間で完成し、操作は単
純簡便で特別の熟練を要しない。なお相分離が完成した
直後の段階で液温を20〜30℃に保ち2例えばヒドロ
キシプロピルメチルセルロースフタレートやアルミニウ
ムレーキ色素を微粉末のまま、あるいは水懸濁液として
投入すると、これらの物質が直ちにコアセルベート表面
に付着し、さらに内部にとりこまれる。この結果、ヒド
ロキシプロピルメチルセルロースフタレートによる腸溶
性マイクロカプセルやアルミニウムレーキ色素による遮
光性着色マイクロカプセルが得られる。これらは本発明
に付加された技術であり、これによって本発明は限定さ
れない。Mention may be made of arginine, lysine, histidine, leucine, isoleucine, and valine. It has also surprisingly been found that water-soluble dyes such as erythrosine, tartrazine, sunset yellow, and brilliant blue also function as inducers in the present invention. Furthermore, in this case, light-shielding colored microcapsules can be obtained using these dyes. The amount of the inducing agent to be added can be small. Specifically, prepare an aqueous solution of the inducing agent in advance, and add the solution already coated with sucrose fatty acid ester or lecithin (with stirring) into the solution. While gradually dropping the inducer and observing the progress of phase separation using a microscope, add the amount necessary to complete the desired phase separation.Therefore, the amount and method of addition of the inducer should be determined as appropriate depending on the situation. Phase separation can be completed in a short time of about 5 to 15 minutes in the case of multi-phase separation, and the operation is simple and easy and does not require any special skill. When the temperature is maintained at 20 to 30°C and 2, for example, hydroxypropyl methyl cellulose phthalate or aluminum lake pigment is introduced as a fine powder or as a water suspension, these substances immediately adhere to the coacervate surface and are further incorporated into the interior. Enteric-coated microcapsules made of hydroxypropyl methylcellulose phthalate and light-shielding colored microcapsules made of aluminum lake dye are obtained.These are techniques added to the present invention, and the present invention is not limited thereby.
最後にマイクロカプセル化の終了した分散液を冷却し、
マイクロカプセルを分離し、水H50、’0エタノール
水、無水エタノールの順序で洗浄し、冷風乾燥してマイ
クロカプセルを単離する。あるいは冷却後にマイクロカ
プセルを含有したまま噴霧乾燥や流動層造粒乾燥にかけ
てマイクロカプセルを取り出してもよい。Finally, the microencapsulated dispersion is cooled,
The microcapsules are separated, washed with H50 water, '0 ethanol water, and absolute ethanol in this order, and dried with cold air to isolate the microcapsules. Alternatively, after cooling, the microcapsules may be taken out by spray drying or fluidized bed granulation drying while still containing the microcapsules.
(4)作用 従来技術に比べ2本発明方法によれば短時間で。(4) Effect Compared to the prior art, the method of the present invention takes a shorter time.
単純簡便な操作により、特別の熟練を要せずにマイクロ
カプセルを製造することができ、得られたマイクロカプ
セルはマイクロカプセルが一般的に有している諸作用2
例えば油状物質の粉末化、不安定物質の経時的安定化、
物質の味、臭の隠蔽化の諸作用を有する。また本発明方
法においては生体に対して安全性の高い物質のみを使用
し2例えばボルムアルデヒドのごとき毒性のある架橋剤
を使用しないので、医薬品の分野において有利に使用す
ることができる。また本発明方法によって得られるマイ
クロカプセルは相分離のための誘起剤として水溶性色素
を使用することにより、あるいは相分離が完成した直後
の段階でアルミニウムレーキ色素を添加することによっ
て、それぞれ容易に遮光性着色マイクロカプセルとする
ことができ。Microcapsules can be produced by simple and easy operations without requiring special skill, and the resulting microcapsules have various functions that microcapsules generally have.
For example, turning oily substances into powder, stabilizing unstable substances over time,
It has the effect of masking the taste and odor of substances. Furthermore, the method of the present invention uses only substances that are highly safe for living organisms and does not use toxic crosslinking agents such as bomaldehyde, so it can be advantageously used in the pharmaceutical field. Furthermore, the microcapsules obtained by the method of the present invention can be easily shielded from light by using a water-soluble dye as an inducer for phase separation, or by adding an aluminum lake dye immediately after phase separation is completed. Can be colored microcapsules.
光に対し不安定な物質を安定化することができる。It can stabilize substances that are unstable to light.
(5)実施例
以下に記載する実施例によって本発明を具体的に説明す
る。(5) Examples The present invention will be specifically explained by the examples described below.
実施例1
エタノール5rnlにシュガーエステルS−970(リ
ョウトウ産業)0.5#およびビタミンEアセテート2
.51Iを50℃で溶解させた。他方、水9Q miに
ヒドロキシプロピルメチルセルロース5.1よびデキス
トラン(分子i 40000 ) 5.9を溶解した溶
液と水20 mlにゼラチン2gを溶解した溶液とを混
合し。Example 1 Sugar ester S-970 (Ryoto Sangyo) 0.5 # and vitamin E acetate 2 in 5 rnl of ethanol
.. 51I was dissolved at 50°C. On the other hand, a solution of 5.1 hydroxypropyl methyl cellulose and 5.9 of dextran (molecules i 40000) dissolved in 9 Q mi of water was mixed with a solution of 2 g of gelatin dissolved in 20 ml of water.
40℃に保持しながら激しく撹拌した。ここに前記ビタ
ミンEアセテート液を徐々に滴下した。山内状態となり
1〜50ミクロンの油滴の表面をシュガーエステルが被
覆している状態が観察された。The mixture was stirred vigorously while maintaining the temperature at 40°C. The vitamin E acetate solution was gradually dropped therein. It was observed that the surface of oil droplets with a size of 1 to 50 microns was coated with sugar ester.
次にゆるく撹拌しながら5%メグルミン溶液2mlを徐
々に添加し、顕微鏡で相分離の進行を観察した。約10
分で完成し球形ないし紡錐形のマイクロカプセルが形成
した。次に28℃に冷却し、水5 mlにヒドロキシプ
ロピルメチルセルロースフタレート0.5.!i’を懸
濁した液を添加した。7°Cに冷却し、マイクロカプセ
ルを分離して冷水100〃+/ 。Next, 2 ml of 5% meglumine solution was gradually added while stirring gently, and the progress of phase separation was observed using a microscope. about 10
The process was completed within minutes, and spherical or spindle-shaped microcapsules were formed. Next, it was cooled to 28°C, and 0.5% of hydroxypropyl methyl cellulose phthalate was added to 5 ml of water. ! A suspension of i' was added. Cool to 7°C, separate the microcapsules, and wash with cold water at 100°C.
50 ”6 工9 /−ル水50rnl、無水エタ/
−ル5Qmlで洗浄し、冷風乾燥して平均直径50ミク
ロンのマイクロカプセルからなる細粒粉末を得た。50 ”6 engineering 9/-le water 50rnl, anhydrous eta/
The microcapsules were washed with 5 Q ml of water and dried with cold air to obtain a fine powder consisting of microcapsules with an average diameter of 50 microns.
実施例2
水100 miにシュガーエステルS−970(リョウ
トウ産業)0.5gを80℃で溶解し、ビタミンEアセ
テ−)2.!M/を添加して分散した。以下の操作を実
施例1記載と同様に行ない、平均直径50ミクロンのマ
イクロカプセルからなる細粒粉末を得た。Example 2 0.5g of Sugar Ester S-970 (Ryoto Sangyo) was dissolved in 100ml of water at 80°C, and vitamin E acetate)2. ! M/ was added and dispersed. The following operations were carried out in the same manner as described in Example 1 to obtain fine powder consisting of microcapsules with an average diameter of 50 microns.
実施例3
ビタミンEアセテートの代わりにビタミンB2を使用し
て実施例1記載と同様に行ない、平均直径20ミクロン
のマイクロカプセルからなる粉末を得た。Example 3 The same procedure as described in Example 1 was carried out using vitamin B2 instead of vitamin E acetate to obtain a powder consisting of microcapsules with an average diameter of 20 microns.
実施例4
ビタミンEアセテートの代わりにビタミンに、を使用し
て実施例1記載と同様に行ない、平均直径100ミクロ
ンのマイクロカプセルからなる細粒粉末を得た。Example 4 The same procedure as described in Example 1 was carried out using vitamin E acetate instead of vitamin A to obtain fine powder consisting of microcapsules with an average diameter of 100 microns.
実施例5
実施例1において5%メグルミン溶液2mlの代わりに
596アルギニン溶液2mlを使用した点を除いて実施
例1記載と同様に行ない、平均直径50ミクロンのマイ
クロカプセルからなる細粒粉末を得た。Example 5 The same procedure as described in Example 1 was carried out except that 2 ml of 596 arginine solution was used instead of 2 ml of 5% meglumine solution in Example 1, to obtain fine powder consisting of microcapsules with an average diameter of 50 microns. .
実施例6
実施例4において5%メグルミン溶液2mトの代わりに
5%タートラジン溶液IQmJを使用した点を除いて実
施例1記載と同様に行ない、平均直径70ミクロンのマ
イクロカプセルからなる細粒粉末を得た。Example 6 The same procedure as described in Example 1 was carried out except that 5% tartrazine solution IQmJ was used instead of 2 m of 5% meglumine solution in Example 4, and a fine powder consisting of microcapsules with an average diameter of 70 microns was prepared. Obtained.
実施例7
実3m例1においてシュガーエステルS−970の代わ
りに大豆レシチンを使用した点を除いて実施例1記載と
同様に行ない、平均直径50ミクロンのマイクロカプセ
ルからなる細粒粉末を得た。Example 7 Example 3 The same procedure as described in Example 1 was repeated except that soybean lecithin was used instead of sugar ester S-970 in Example 1 to obtain a fine powder consisting of microcapsules with an average diameter of 50 microns.
実施例8
実施例1においてヒドロキシプロピルメチルセルロース
5gの代わりにメチルセルロース1gを使用した点を除
いて実施例1記載と同様に行ない。Example 8 The same procedure as described in Example 1 was carried out except that 1 g of methyl cellulose was used instead of 5 g of hydroxypropyl methyl cellulose.
平均直径50ミクロンのマイクロカプセルからなる細粒
粉末を得た。A fine powder consisting of microcapsules with an average diameter of 50 microns was obtained.
(6)発明の効果
実験例1
実施例1においてシュガーエステルS−970を使用し
ない点を除いて実施例1記載と同様に行った。(6) Effect of the Invention Experimental Example 1 The same procedure as described in Example 1 was conducted except that sugar ester S-970 was not used in Example 1.
その結果、ビタミンEアセテートの油滴の周囲にコアセ
ルベートが堆積されず、マイクロカプセルが形成されな
かった。実施例1においてはマイクロカプセルが形成さ
れたことと対比すると、あらかじめシュガーエステルS
−970によって被覆することが必須であることが判明
した。As a result, coacervate was not deposited around the vitamin E acetate oil droplets, and no microcapsules were formed. In contrast to the formation of microcapsules in Example 1, sugar ester S
-970 was found to be essential.
実験例2
試料と方法
表1記載の仕込処方(重量比)による三種類のマイクロ
カプセルを本発明方法によって製造し。Experimental Example 2 Samples and Methods Three types of microcapsules were produced according to the formulation (weight ratio) shown in Table 1 by the method of the present invention.
試料1〜3として用意した。試料1は非着色マイクロカ
プセル、試料2.試料3は着色マイクロカプセルである
。各試料に1000ルツクスの光を照射し、経日的にビ
タミンに、含意を測定し、残存率を求めた。なお、ビタ
ミンに2の測定はUnisel QC18カラムを用い
る高速液体クロマト法で行ない。Samples 1 to 3 were prepared. Sample 1 is non-colored microcapsule, sample 2. Sample 3 is a colored microcapsule. Each sample was irradiated with 1000 lux light, and the vitamin content was measured over time to determine the residual rate. Note that the measurement of vitamin 2 was performed by high performance liquid chromatography using a Unisel QC18 column.
吸光波長248 nmでのピークの高さより試料100
=中のビタミンに2含量を求めた。Sample 100 from the peak height at absorption wavelength 248 nm
= The content of 2 vitamins in it was determined.
表1
試料1 試料2 試料3
ビタミ7に、 1 1 1ゼラチ
ン 2 2 2
シユガーエステル 0.25 0.25 0.25
メグルミン o、os −o、osエリス
ロシン −0,08−
結果
結果を図1に示す。図中・印線、Δ印線、○印線はそれ
ぞれ試料1.試料2.試料3の結果を示す。図1より本
発明方法によって得られるマイクロカプセルは相分離の
ための誘起剤として水溶性色素を使用することにより、
あるいは相分離が完成した直後の段階でアルミニウムレ
ーキ色素を添加することlこよってそれぞれ容易に遮光
性着色マイクロカプセルとすることができ、光に対して
不安定な物質を安定化することができることが判明する
。Table 1 Sample 1 Sample 2 Sample 3 Vitamin 7, 1 1 1 Gelatin 2 2 2 Sugar ester 0.25 0.25 0.25
Meglumine o, os -o, os erythrosin -0,08- Results The results are shown in Figure 1. In the figure, the marked lines, Δ marked lines, and ○ marked lines are for sample 1. Sample 2. The results of sample 3 are shown. From Figure 1, the microcapsules obtained by the method of the present invention can be obtained by using a water-soluble dye as an inducer for phase separation.
Alternatively, it is possible to add an aluminum lake dye immediately after phase separation is completed, thereby easily forming light-shielding colored microcapsules and stabilizing substances that are unstable to light. Prove.
図1はマイクロカプセルに対する光照射の実験結果であ
り、照射時間と残存率の関係を示すグラフである。FIG. 1 shows the experimental results of light irradiation on microcapsules, and is a graph showing the relationship between irradiation time and survival rate.
Claims (7)
性物質のマイクロカプセルを製造するにあたり、あらか
じめ当該水難溶性物質をショ糖脂肪酸エステルまたはレ
シチンによって被覆してから、当該相分離のための誘起
剤を添加することを特徴とするマイクロカプセルの製造
方法(1) When producing microcapsules of a poorly water-soluble substance by phase separation of a film-forming polymer composition, the poorly water-soluble substance is coated in advance with sucrose fatty acid ester or lecithin, and then induced for phase separation. A method for producing microcapsules characterized by adding an agent
る組成物である特許請求の範囲第1項記載のマイクロカ
プセルの製造方法(2) The method for producing microcapsules according to claim 1, wherein the film-forming polymer composition is a composition containing gelatin as a main component.
ン、非イオン性セルロース誘導体からなる組成物である
特許請求の範囲第1項記載のマイクロカプセルの製造方
法(3) The method for producing microcapsules according to claim 1, wherein the film-forming polymer composition is a composition comprising gelatin, dextran, and a nonionic cellulose derivative.
ルメチルセルロースまたはメチルセルロースである特許
請求の範囲第3項記載のマイクロカプセルの製造方法(4) The method for producing microcapsules according to claim 3, wherein the nonionic cellulose derivative is hydroxypropylmethylcellulose or methylcellulose.
チジン、ロイシン、イソロイシン、バリンのいづれかで
ある特許請求の範囲第1項ないし第4項記載のマイクロ
カプセルの製造方法(5) The method for producing microcapsules according to claims 1 to 4, wherein the inducer is any one of meglumine, arginine, lysine, histidine, leucine, isoleucine, and valine.
ないし第4項記載のマイクロカプセルの製造方法(6) The method for producing microcapsules according to claims 1 to 4, wherein the inducing agent is a water-soluble dye.
セットイエロー、ブリリアントブルーのいづれかである
特許請求の範囲第6項記載のマイクロカプセルの製造方
法(7) The method for producing microcapsules according to claim 6, wherein the water-soluble dye is any one of erythrosine, tartrazine, sunset yellow, and brilliant blue.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP20798886A JPS6365945A (en) | 1986-09-05 | 1986-09-05 | Preparation of microcapsule |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP20798886A JPS6365945A (en) | 1986-09-05 | 1986-09-05 | Preparation of microcapsule |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS6365945A true JPS6365945A (en) | 1988-03-24 |
Family
ID=16548820
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP20798886A Pending JPS6365945A (en) | 1986-09-05 | 1986-09-05 | Preparation of microcapsule |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS6365945A (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0350246A2 (en) * | 1988-07-05 | 1990-01-10 | Takeda Chemical Industries, Ltd. | Sustained release microcapsule for water soluble drug |
JPH0753356A (en) * | 1993-08-16 | 1995-02-28 | Morishita Jintan Kk | Seamless capsule containing easily oxidizable oily substance and its production |
JPH10502621A (en) * | 1994-07-01 | 1998-03-10 | エフ・ホフマン−ラ ロシユ アーゲー | Multiple microencapsulation of lipophilic substances |
JP2003508195A (en) * | 1999-08-27 | 2003-03-04 | メーヌラブ | Method for encapsulating active substances by coacervation of polymer in non-chlorinated organic solvents |
JP2004075582A (en) * | 2002-08-13 | 2004-03-11 | Takeda Chem Ind Ltd | Method for stabilizing ingredient other than active ingredient prescribed in solid pharmaceutical composition |
JP2013519499A (en) * | 2010-02-15 | 2013-05-30 | ネステク ソシエテ アノニム | Liquid-filled protein-phosphatidic acid capsule dispersion |
JP2013519518A (en) * | 2010-02-18 | 2013-05-30 | ネステク ソシエテ アノニム | Dispersion of liquid filled chitosan-anionic lipophilic surfactant capsules |
KR20160148028A (en) * | 2014-05-05 | 2016-12-23 | 바스프 에스이 | Formulation of fat-soluble vitamin |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5858146A (en) * | 1981-10-05 | 1983-04-06 | Tanabe Seiyaku Co Ltd | Microcapsule with fast releasability and preparation thereof |
-
1986
- 1986-09-05 JP JP20798886A patent/JPS6365945A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5858146A (en) * | 1981-10-05 | 1983-04-06 | Tanabe Seiyaku Co Ltd | Microcapsule with fast releasability and preparation thereof |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0350246A2 (en) * | 1988-07-05 | 1990-01-10 | Takeda Chemical Industries, Ltd. | Sustained release microcapsule for water soluble drug |
JPH0753356A (en) * | 1993-08-16 | 1995-02-28 | Morishita Jintan Kk | Seamless capsule containing easily oxidizable oily substance and its production |
JPH10502621A (en) * | 1994-07-01 | 1998-03-10 | エフ・ホフマン−ラ ロシユ アーゲー | Multiple microencapsulation of lipophilic substances |
JP2003508195A (en) * | 1999-08-27 | 2003-03-04 | メーヌラブ | Method for encapsulating active substances by coacervation of polymer in non-chlorinated organic solvents |
JP2004075582A (en) * | 2002-08-13 | 2004-03-11 | Takeda Chem Ind Ltd | Method for stabilizing ingredient other than active ingredient prescribed in solid pharmaceutical composition |
JP2013519499A (en) * | 2010-02-15 | 2013-05-30 | ネステク ソシエテ アノニム | Liquid-filled protein-phosphatidic acid capsule dispersion |
JP2013519518A (en) * | 2010-02-18 | 2013-05-30 | ネステク ソシエテ アノニム | Dispersion of liquid filled chitosan-anionic lipophilic surfactant capsules |
KR20160148028A (en) * | 2014-05-05 | 2016-12-23 | 바스프 에스이 | Formulation of fat-soluble vitamin |
JP2017521359A (en) * | 2014-05-05 | 2017-08-03 | ビーエーエスエフ ソシエタス・ヨーロピアBasf Se | Fat-soluble vitamin preparation |
US11090276B2 (en) | 2014-05-05 | 2021-08-17 | Basf Se | Formulation of fat-soluble vitamin |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3043782A (en) | Process for preparing a more impermeable coating by liquid-liquid phase separation | |
US3655406A (en) | Carotenoid compositions | |
JP2564386B2 (en) | Method for preparing powder of water-insoluble polymer | |
EP0498824B2 (en) | Process of preparing a water dispersible hydrophobic or aerophilic solid | |
US4389419A (en) | Vitamin encapsulation | |
JP4124821B2 (en) | Stable aqueous dispersions of xanthophylls and stable water-dispersible dry powders, their production and use | |
KR100392215B1 (en) | Multiple encapsulation of lipophilic substances | |
JP3694240B2 (en) | Stable aqueous dispersion of xanthophyll and stable dry powder dispersible in water, and its manufacture and use | |
JP2620277B2 (en) | Powdery water-dispersible carotenoid preparation and process for producing the same | |
JP4437041B2 (en) | How to obtain a new formulation based on lutein | |
Huang et al. | Microencapsulation of extract containing shikonin using gelatin–acacia coacervation method: a formaldehyde-free approach | |
JPH0366615A (en) | Manufacture of new colloid dispersion carotinoid preparation | |
JPS62240364A (en) | Production of fine granular carotinoid product dispersible in water | |
JPH0335347B2 (en) | ||
EP0982038B1 (en) | Stable powdery vitamin and carotenoide containing compositions and process to prepare them | |
JPS60116627A (en) | Manufacture of microspheres for intervascular transportation | |
JPS63258641A (en) | Manufacture of microcapsules | |
CN105663082B (en) | A kind of strong anti-oxidation Xanthophyll micro-capsule and preparation method thereof | |
AU2009213074A1 (en) | Microencapsulation systems and applications of same | |
WO2016119143A1 (en) | Lutein microcapsule preparation and preparation method | |
Horn | Preparation and characterization of microdisperse bioavailable carotenoid hydrosols | |
JPS6365945A (en) | Preparation of microcapsule | |
KR20100131369A (en) | Novel preparation of an enteric release system | |
JP2002504425A (en) | Matrix for producing microparticles or nanoparticles, method for producing said particles and particles obtained | |
JP2003518509A (en) | Granular vitamin composition |